
    
      This is a first-in-human, open-label, multicenter, dose escalation study designed to
      determine the safety and tolerability of RPTR-147 as a monotherapy and in combination with
      Pembrolizumab in patients with selected solid tumors or lymphomas.

      The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion
      (Phase 2).
    
  